Facilitated By

San Antonio Medical Foundation

A Single-Center, Open-Label Phase 2A Clinical Trial To Evaluate the Safety and Efficacy of GR-MD-02 for the Treatment of Patients with Moderate To Severe Plaque Psoriasis

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Principal Investigator(s)
Email for information
Funded by
Geneva Foundation
Research Start Date
Status
Active

The overall objective is to establish the safety and efficacy of GR-MD-02 in patients with moderate to severe plaque psoriasis<p>Primary Objective - The objective is to evaluate the number of patients with moderate to severe plaque psoriasis who have 75% improvement in Psoriasis Activity Severity Index (PASI-75) following 12 weeks of therapy with GR-MD-02</p><p>Secondary Objectives - </p><p>To determine the PASI-50 and PASI-100 scores in patients with moderate to severe plaque psoriasis following the first 12 weeks of therapy with GR-MD-02</p><p>To determine the PASI-50, PASI-75, and PASI-100 scores in patients with moderate to severe plaque psoriasis following an additional 12 weeks of therapy (total 24 weeks) with GR-MD-02</p><p>To determine the durability of response to therapy in responders over a one year period following the end of therapy</p><p>To determine whether there is any change in disease status of patients who also have psoriatic arthritis</P>To determine the incidence of adverse events and vital sign and laboratory abnormalities during study treatment</p>

Clinical Care
Infectious Disease
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.